Healthcare
Live Price
Offline$44.15
+0.00% today
1Y Change
—
Window
No data
Historical coverage is still loading
We are still backfilling 1Y daily history for this symbol. Some charts may stay empty until more data arrives.
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Albireo Pharma, Inc. (ALBO) is a Healthcare stock with a market cap of $915.89M. The stock last traded around $44.15. Baseline metrics include revenue growth of +388.4%, EPS growth of -5.6%, a dividend yield of 0.0%. What stands out right now is revenue +388.4%, EPS -5.6%, free cash flow -6.8% with operating margin -304.3% and ROIC -48.1%. Valuation already assumes a fairly strong business story at price/sales 22.6. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines ALBO price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
ALBO
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
ALBO Max Drawdown
—
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for ALBO and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$1.0K
-100.0% YoY
FY Net Income
-$24.4M
+47.1% YoY
Free Cash Flow
-$27.8M
-3.3% YoY
Revenue Growth
+388.4%
EPS Growth
-5.6%
Gross Margin
96.7%
Net Margin
-373.0%
Income statement
USD
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|
| Revenue | 41M | 8M | 10M | 13M | 1K |
| Gross Profit | 39M | 8M | 7M | 13M | 1K |
| Operating Income | -123M | -96M | -61M | -38M | -25M |
| EBITDA | -20M | -96M | -57M | -38M | -24M |
| Net Income | -151M | -119M | -72M | -46M | -24M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|
| Cash & Equivalents | 248M | 251M | 132M | 164M | 53M |
| Total Assets | 302M | 286M | 165M | 185M | 73M |
| Total Liabilities | 126M | 104M | 72M | 63M | 8M |
| Shareholder Equity | 176M | 181M | 93M | 123M | 65M |
| Total Debt | 10M | 10M | 0 | 0 | 0 |
| Net Debt | -238M | -242M | -132M | -164M | -53M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
28M
-2.9% YoY
Capital Expenditures
190K
-211.5% YoY
Free Cash Flow
28M
-3.3% YoY
Key ratios
Gross Margin
96.7%
Operating Margin
-304.3%
Net Margin
-373.0%
ROE
-84.8%
Debt / Equity
0.06x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.